Siblings 圖書 [1/1] 期刊論文 [327/330] Collection Statistics 近3年內發表的文件:16(8.94%) 含全文筆數:115(64.25%) 文件下載次數統計 下載大於0次:115(100.00%) 下載大於100次:112(97.39%) 檔案下載總次數:39303(22.07%) 最後更新時間: 2024-12-01 07:53 Top Upload Loading... Top Download Loading... Recent Submissions Single-cell RNA sequencing via Endo... Nivolumab plus ipilimumab (N plus I... Risk of type 2 diabetes mellitus an... Phase 1 studies of D07001-F4 and D0... Updated overall survival (OS) from ... Outcomes of post-immunotherapy dura... Updated overall survival (OS) from ... Updated results of the FOENIX-CCA2 ... Comparative genomic analysis and it... A phase II trial of nivolumab, gemc...

Jump to a point in the index: (Choose year) 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 2001 2000 1999 1998 1997 1996 1995 1994 1993 1992 1991 1990 1985 1980 1975 1970 1960 1950 (Choose month) January February March April May June July August September October November December Or type in a year:

Ordering With Most Recent First Show Oldest First

Showing items 41-50 of 179. (18 Page(s) Totally) << < 1 2 3 4 5 6 7 8 9 10 > >> View [10|25|50] records per page

Date	Title	Relation
2018-11	Liposomal irinotecan (nal-IRI) plus 5-FU/LV in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) progressing on gemcitabine-based treatment: Further subgroup analyses of the pivotal NAPOLI-1 study	Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 200P.
2018-11	M7824 (MSB0011359C), a bifunctional fusion protein targeting transforming growth factor beta (TGF-beta) and PD-L1, in Asian patients with pretreated biliary tract cancer (BTC): Efficacy by BTC subtype	Annals of Oncology. 2018 Nov;29(Suppl. 9):Meeting Abstract 153O.
2018-11	TCOG T1308 study: The final results of a phase II trial of modified gemcitabine plus S-1 combination as the first-line treatment in patients with advanced biliary tract cancer	Annals of Oncology. 2018 Nov;29(Suppl. 9):50.
2018-10	NAPOLI-1 phase III trial outcomes by prior surgery, and disease stage, in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC)	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 733P.
2018-10	The prognostic value of the modified glasgow prognostic score (mGPS) in predicting overall survival (OS) in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving liposomal irinotecan (nal-IRI)+5-fluorouracil and leucovorin (5-FU/LV)	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 749P.
2018-10	Impact of dose reduction or dose delay on the efficacy of liposomal irinotecan (nal-IRI)+5-fluorouracil/leucovorin (5-FU/LV): Survival analysis from NAPOLI-1	Annals of Oncology. 2018 Oct;29(Suppl. 8):250-251.
2018-10	M7824 (MSB0011359C), a bifunctional fusion protein targeting PD-L1 and TGF-beta, in Asian patients with pretreated biliary tract cancer: Preliminary results from a phase I trial	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 757P.
2018-10	Multicenter, phase II trial of biweekly S-1, leucovorin (LV), oxaliplatin and gemcitabine (SLOG) in metastatic pancreatic adenocarcinoma (mPDAC): Final report of TCOG T1211 study	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 736P.
2018-10	Randomized, phase III trial comparing adjuvant gemcitabine (Gem) versus Gem plus chemoradiation (CCRT) in curatively resected pancreatic ductal adenocarcinoma (PDAC): A Taiwan cooperative oncology group study	Annals of Oncology. 2018 Oct;29(Suppl. 8):Meeting Abstract 626PD.
2018-09	Nivolumab safety profile in Asian and Western patients with chemotherapy-refractory (CTx-R) advanced gastric/gastroesophageal junction (adv G/GEJ) cancer from the ATTRACTION-2 and CheckMate-032 trials	Oncology Research and Treatment. 2018 Sep;41(Suppl. 4):285-286.

Showing items 41-50 of 179. (18 Page(s) Totally) << < 1 2 3 4 5 6 7 8 9 10 > >> View [10|25|50] records per page